IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Aurisicchio, et al.	
Filed: Feb	To Be Assigned ruary 9, 2006 HETIC GENE ENCODING RHESUS MONKEY INOEMBRYONIC ANTIGEN AND USES EOF	

Commissioner for Patents P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

Merche co., INC.
Salviel Schowley 2/9/04

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited

by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120

are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		
		-		
		-		
If this is inconvenient, additional copies will be submitted upon requi	est.			
6. In accordance with 37 C.F.R. 1.97, (check one)				
the attached information is filed within three months of the filing	date of the captioned case.			
the attached information is filed more than three months after the Office Action on the merits.	e filing date but prior to the	mailing of a first		
the attached information is filed before the mailing of a first Offic examination under §1.114.	e action after the filing of a	request for continued		
the attached information is being filed more than three months a Office Action on the merits, but before the mailing date of a Fina otherwise closes prosecution in the application. The enclosed a Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(I Action, Notice of Allowand uthorization is therefore give	e, or an action that		
each item of information contained in this Information Disclosure from a foreign patent office in a counterpart foreign application in Statement.				
each item of information contained in the information disclosure from a foreign patent office in a counterpart application and this designated in §1.56(c) more than thirty days prior to the filing of	communication was not red	eived by any individual		
no item of information contained in this Information Disclosure S foreign patent office in a counterpart foreign application, and, to after making reasonable inquiry, was known to any individual de months prior to the filing of this Statement.	the knowledge of the perso	n signing the certification		
	Respectfully submitted,	1		

By: Alysia A. Finnegan

Attorney For Applicant(s)

Reg. No. 48,878 MERCK & CO., INC. Patent Dept., RY60-30

P.O. Box 2000 Rahway, N.J. 07065-0907

(732)594-2583

(732)394-<u>2363</u>

IAP20 RES SUBSTITUTE	== ₫ _		0 -4	33.484	
10000000	2.1	~ D	amund for use I	- Aug 7 102005	OMB 06514
SUBSTITUTE	or PTQ/SB	108 A (07	05), Informati	on Disclosure Stat	ement by Appl
If it ime con-	rutcht a			2 DELVICIBLE	OF COMME

					Tach and Trademark Office, 0.3 DEFARTMENT OF COMMERC		
	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
1	NFORMATION	DIS	CLOSURE	Application Number	To Be Assamed # 20 66 3 3 8		
	TATERATERITE IN	. A TI	DITCANT	Filing Date	February 9, 2006		
STATEMENT BY APPLICANT				First Named Inventor	Aurisicchio, et al.		
				Group Art Unit			
	(use as many sheets	as r	necessary)	Examiner Name			
Sheet	1	of	3	Attorney Docket Number	ITR0058P		

		U.S. PA	ATENT DOCUMENTS	
Cite No.	U.S. Patent Docur Number	nent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	5,274,087		Barnett, et al.	12/28/1993
	5,571,710		Barnett, et al.	11/05/1996
	5,698,530		Schlom, et al.	12/16/1997
	5,843,761		Barnett, et al.	12/01/1998
				ı
		Cite No. Number 5,274,087 5,571,710 5,698,530	Cite No. V.S. Patent Document S. 274,087 Kind Code (g/t known) 5,274,087 F. S. 271,010 5,698,530 Inc. 2012	Cite No. Number Kind Code (nf shown) Name of Patentee or Applicant of Cited Document 5,274,087 Barnett, et al. 5,571,710 Barnett, et al. 5,698,530 Schlom, et al.

					DOCUMENT	Ś	
Examiner initials*	No.	Office	Foreign Patent Docume Number	Kind Code (if known)	of C	Patentee or Applicative Document	Date of Publication of Cited Document MM-DD-YYYY
/B.P.	<i>/</i>	PCT	WO 01/24832		Pecher		04/12/2001
		PCT	WO 01/30382		Aventis Pasteur	Limited	05/03/2001
		PCT	WO 02/022080		Merck & Co., I	nc.	03/21/2002
		PCT	WO 02/38769		Muller		05/16/2002
		PCT	WO 03/018055		Merck		03/06/2003
		PCT	WO 03/059379		Pharmexa		07/24/2003
		PCT	WO 04/072287		Merck		
		PCT	WO 2004/092216		Trangene S.A.		10/28/2004
VZ		PCT	WO 04/099247		Merck		
W		EP	0 346 710		Miles, Inc.		06/03/1989
Examin Signatu			/Bo Peng/			Date Considered	02/29/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AP20 Part of PG 18 FTD 09 FEB. 2006 Approved for one thorough 70 17000. ONE 0031-0031
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000. ONES 0031-0031
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000. ONES 0031-0031
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000. ONES 0031-0031
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000. ONES 0031-0031
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000. ONES 0031-0031
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Superior Science by Approved for one thorough 70 17000.
Part and Trademics Office to Science by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Approved for one thorough 70 17000.
Part and Trademics Office by Appro

COMPLETE IF KNOWN Substitute for form 14498/PTO To Be As TO 1500 200 Application Number INFORMATION DISCLOSURE Filing Date February 9, 2006 STATEMENT BY APPLICANT First Named Inventor Aurisicchio, et al. Group Art Unit (use as many sheets as necessary) Examiner Name Sheet 2 of 3 Attorney Docket Number ITR0058P

			NON PATENT LITERATURE DOCUMENTS
Exam Initia		Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/B.P./			Andre, et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage", J. of Virol., Feb. 1998, Vol. 72, No. 2, pp. 1497-1503.
			Beauchemin, et al. "Isolation and Characterization of Full-Length Functional cDNA Clones for Human Carcinoembryonic Antigen", Molecular and Cellular Biology, Vol. 7, No. 9, pp. 3221-3230, Sept. 1987.
			Benchimol, et al., "Carcinoembryonic Antigen, a Human Tumor Marker, Functions as an Intercellular Adhesion Molecule", Cell, Vol. 57, pp. 327-334, April 21, 1989.
			Berinstein, et al., "Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: a Review", J. of Clinical Oncology, Vol. 20, No. 8, pp. 2197-2207, April 15, 2002.
			Chester, et al., "Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer", Cancer Chemother. Pharmacol., Vol. 46 (Suppl) S8-S12, 2000.
			Facciabene, "Baculovirus Vectors Elicit Antigen-Specific Immune Responses in Mice", J. of Virol., Aug. 2004, Vol. 78, No. 16, pp. 8663-8672.
			Gold, et al., "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques", J. Exp. Med., Vol. 121, pp. 439-462 (1965).
	Hami Vol.		Hammarstrom, et al., "Is There a Role for CEA in Innate Immunity in the Colon", Trends in Microbiology, Vol. 9, No. 3, pp. 119-125, 2001.
			Horig, et al., "Strategies for cancer therapy using carcinoembryonic antigen vaccines", Expert Reviews in Molecular Medicine Electronic Resource, Vol. 2000, pp. 1-24, 2000.
			Jantscheff, et al., "Search for CEA-Like Molecules In Polymorphonuclear leukocytes of non-human primates using monoclonal antibodies", Archiv. Fur Feschwulsforschung, Vol. 56, No. 2, 1986, pp. 113-6.
			Kantor, et al., "Immunogenicity and Safety of a Recombinant Vaccinia Virus Vaccine Expressing the Carcinoembryonic Antigen Gene in a Nonhuman Primate", Cancer Research, Vol. 52, pp. 6917-6925, 1992.
			Kim, et al., "Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells", Gene, Vol. 191, pp. 293-301, 1997.
			Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data", J. Mol. Biol., Vol. 183, pp. 1-12, 1985.
			Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors", DNA and Cell Biology, Vol. 12, No. 9, pp. 777-783, 1993.
	/		Paxton, et al., "Sequence Analysis of Carcinoembryonic Antigen:Identification of Glycosylation Sites and Homology With the Immunoglobulin Supergene Family", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 920-924, February 1987.

Examiner Signature	/Bo Peng/	Date Considered	02/29/2008)
				-

(A) 1972 I SUBSTATURE OF PER SHOULD DE 160 PER SHOULD DE PRIME DE 1700 DE

Substitute for form 1449B/PTO
INFORMATION DISCLO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number
To Be Assigned
To

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/B.P./		Scholl, et al., "Gene Therapy Applications to Cancer Treatment", J. of Biomedicine and Biotechnology", 2003:1, pp. 35-47, 2003.
		Screaton, et al., "Carcinoembryonic Antigen, A Human Tumor Marker, Cooperates with Myc and Bel-2 in Cellular Transformation", J. of Cell Biology, Vol. 137, No. 4, pp. 939-952, May 19, 1997.
		Shiver, et al., "Cytotoxic T Lymphocyte and Helper T Cell Responses following HIV Polynucleotide Vaccination", Annals. New York Academy of Sciences, Vol. 772, pp. 198-208, 1995.
		Taheri, et al., "Self Recognition in the Ig Superfamily", J. of Biol. Chem., Vol. 275, No. 35, Sept. 2000, pp. 26935-26943.
		Thompson, et al., "Molecular cloning of a gene belonging to the carcinoembryonic antigen gene family and discussion of a domain model", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 2965-2969, May 1987.
		Wheeler, et al., "Safety and Immunogenicity of a recombunant vaccinia virus vaccine expressing a 70kDa fragment of the human acarionembryonic antigen in a nonhuman primate", Proceedings of the American Association for Cancer Research", Vol. 36, March 1935, pp. 366.
\bigvee		Virji, et al., "CEA and innate immunity", TRENDS in Microbiology, Vol. 9, No. 6, June 2001, pp. 258-259.

Examiner Signature	/Bo Peng/	Date Considered	02/29/2008)				
*Byaminar Initial if as ferrors considered whether or not citation is in the Company with MDED COO. Down live through station if our in the citation is in the citation in the citation in the citation is in the citation in the citation in the citation is in the citation in the citation in the citation is in the citation in the citation in the citation is in the citation in the cit								